厄贝沙坦治疗高血压早期肾损害的疗效观察

目的:探讨厄贝沙坦治疗高血压早期肾损害的临床疗效。方法:选取80例高血压早期肾损害病人，按照随机数字表法分为2组:氨氯地平组40例，给予氨氯地平治疗；厄贝沙坦组40例，给予厄贝沙坦治疗。治疗12周后比较2组的血压、肾功能、血管内皮功能。结果:2组病人收缩压、舒张压和平均动脉压均明显低于治疗前（P<0.01），组间比较差异均无统计学意义（P>0.05）；厄贝沙坦组24h尿蛋白排泄率及β2微球蛋白水平均明显低于氨氯地平组，一氧化氮、内皮舒张功能均明显高于氨氯地平组，内皮素水平低于氨氯地平组（P<0.05~P<0.01）；2组病人不良反应发生率差异无统计学意义（P>0.05）。结论:厄贝沙坦与氨氯地平均可有效降低高血压早期肾损害的血压，但在改善肾功能、血管内皮功能方面，厄贝沙坦的效果更好，值得临床重视。

Analysis of clinical efficacy of irbesartan in the treatment of early renal damage of hypertension

Objective:To investigate the clinical efficacy of irbesartan in the treatment of early renal damage of hypertension.Methods:Eighty hypertensive patients with early renal damage were randomly divided into the amlodipine group and irbesartan group(40 cases each group).The amlodipine group and irbesartan group were treated with amlodipine and irbesartan,respectively.After 12 weeks of treatment,the blood pressure,renal function and vascular endothelial function were compared between two groups.Results:The systolic blood pressure,diastolic blood pressure and mean arterial pressure in two groups after treatment were significantly lower than before treatment(P<0.01),there was no statistical significance between two groups(P>0.05).The levels of 24 h UAER and β2-MG in irbesartan group were significantly lower than those in amlodipine group,the NO and vascular endothelial function in irbesartan group were significantly higher than those in amlodipine group,and the ET level in irbesartan group was significantly lower than that in amlodipine group(P<0.05 to P<0.01).The difference of the incidence rate of adverse reaction between two groups was not statistically significant(P>0.05).Conclusions:Irbesartan and amlodipine can effectively reduce the blood pressure in hypertension patients with early renal damage.The effect of irbesartan in improving renal and vascular endothelial function is better than that of amlodipine,and the use of irbesartan is worthy of attention.